• Target：
• FoxD3

• Gene Name：
• FOXD3

• Protein Name：
• Forkhead box protein D3

• Human Gene Id：
• 27022

• Human Swiss Prot No：
• Q9UJU5

• Mouse Gene Id：
• 15221

• Mouse Swiss Prot No：
• Q61060

• Immunogen：
• Purified recombinant fragment of human FoxD3 expressed in E. Coli.

• Specificity：
• FoxD3 Monoclonal Antibody detects endogenous levels of FoxD3 protein.

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Monoclonal, Mouse

• Dilution：
• WB 1:500 - 1:2000. IHC 1:200 - 1:1000. ELISA: 1:10000.. IF 1:50-200

• Purification：
• Affinity purification

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• FOXD3;HFH2;Forkhead box protein D3;HNF3/FH transcription factor genesis

• Molecular Weight(Da)：
• 48kD

• References：
• 1. J Neuroimmune Pharmacol. 2009 Mar;4(1):103-15.
  2. Nature. 2006 May 18;441(7091):315-21.

• Background：
• This gene belongs to the forkhead family of transcription factors which is characterized by a distinct forkhead domain. Mutations in this gene cause autoimmune susceptibility 1. [provided by RefSeq, Nov 2008],

• Function：
• disease:Defects in FOXD3 are associated with susceptibility to autoimmune disease type 1 (AIS1) [MIM:607836]; also called vitiligo-associated multiple autoimmune disease susceptibility type 2 (VAMAS2). Generalized vitiligo is an acquired disorder in which white patches of skin and hair result from autoimmune loss of melanocytes, often associated with other autoimmune disorders. Most cases occur in a sporadic family pattern suggesting polygenic, multifactorial inheritance. However, a striking family in which a somewhat unusual vitiligo phenotype has been described, characterized by progressively coalescent diffuse depigmentation and relatively early disease onset, segregated as an apparent autosomal dominant with incomplete penetrance.,function:Binds to the consensus sequence 5'-A[AT]T[AG]TTTGTTT-3' and acts as a transcriptional repressor. Also acts as a transcriptional activator. Promote

• Subcellular Location：
• Nucleus .

• Expression：
• Expressed in chronic myeloid leukemia, Jurkat T-cell leukemia and teratocarcinoma cell lines, but not in any other cell lines or normal tissues examined.

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs